Observational studyCardiovascular intervention and therapeutics2025
Calcium channel blocker use and outcomes following transcatheter aortic valve intervention for aortic stenosis.
Observational study in Cardiovascular intervention and therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Hypertension and Valvular Heart Disease: An Overview of a Complex and Clinically Meaningful Relationship.Life (Basel, Switzerland) · 2026Review
- Prognostic Utility of Left Ventricular Ejection Fraction in Patients Undergoing Transcatheter Aortic Valve Implantation - A Systematic Review and Meta-Analysis.Circulation reports · 2025Article
- Sodium-Glucose Cotransporter 2 Inhibitors in Aortic Stenosis: Toward a Comprehensive Cardiometabolic Approach.International journal of molecular sciences · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Calcium channel blockers (CCBs) are commonly used to treat coronary artery disease (CAD). The effects of the use of CCBs on the prognosis of patients with aortic stenosis (AS) after transcatheter aortic valve intervention (TAVI) has not been explored. This study elucidated the effects of the use of CCBs on clinical outcomes of patients who underwent TAVI for severe AS. This retrospective observational study included 993 consecutive patients who underwent TAVI for severe AS between January 2017 and July 2023. All patients were followed up for all-cause mortality and hospitalisation for heart failure. Composite endpoints between patients with and without CCBs at discharge were compared using propensity score matching (PSM). CCBs were administered to 590 (59.4%) patients following TAVI. Over a median follow-up period of 719 (335-1,120) days, the composite endpoint occurred in 269 patients. After PSM, there was no significant difference in the composite endpoint between the two groups (hazard ratio = 0.879; p = 0.409). Subgroup analysis revealed that the use of CCBs was associated with a better prognosis in the CAD subgroup (p for interaction = 0.002). This study does not suggest that the use of CCBs is associated with worse clinical outcomes in patients after TAVI for severe AS. Additionally, the use of CCBs may lead to a better prognosis in patients with CAD.
Indexed as
Identifiers
39899262What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.